Skip to main content
Delfa

← All trials/NCT06475586

CompletedPhase 4

Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

Effect of Semaglutide on the Inflammatory Response and Clinical Course of Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

-

Actual enrollment

30

Study population

Psoriasis / psoriatic arthritis, Type 2 diabetes

Eligibility highlights

-

Primary endpoints

•Clinical characteristics of patients with psoriasis•Determine BMI Body Mass Index•Serum values of TNFa, IL-1b, IL-6, IL-17 and IL-23

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06475586
Org study ID18/4.48/23

Timeline

Milestones

Study start2023-05-03actual
Primary completion2024-03-01actual
Study completion2024-06-10actual
Study first posted2024-06-26actual
Last update posted2024-07-01actual

Assets

Investigational agents

Semaglutide

Who this study enrolls

Psoriasis / psoriatic arthritisType 2 diabetes

Who can enroll

Minimum age18 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Patients who signed a personal consent to participate in the study,
•Patients with a typical clinical picture of moderately-severe to severe plaque psoriasis (PASI SCORE ≥10) and
•DMT2 diagnosed at least 6 months before inclusion in the study,
•Patients who were not treated with immunosuppressive therapy.

Exclusion criteria

•Other forms of psoriasis,
•Other chronic, inflammatory diseases (data obtained by reviewing the medical history),
•Drugs that can cause the appearance of psoriasis (lithium, systemic antimalarials, systemic corticosteroids) - for the past 3 months,
•Systemic therapy of vulgaris psoriasis 3 months before inclusion in the study,
•Patients on therapy with other GLP-1 RAs except semaglutide (liraglutide, dulaglutide, lixisenatide), SGLT-2 inhibitors (empagliflozin and dapagliflozin) and NSAIDs, photo UVB therapy,
•Patients who did not personally sign consent to participate in the study.

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
3
Other (unclassified)
3
Cardiometabolic biomarkers
2
Weight & body composition
1
Other clinical outcomes
1

Weight & body composition

1 endpoint
Primary/protocol endpoint

Determine BMI Body Mass Index

Time frame:up to 12 weeks

descriptive

Glycemic / diabetes

3 endpoints
Primary/protocol endpoint

Change in HgbA1C,

Time frame:up to 12 weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Primary/protocol endpoint

fasting insulin

Time frame:up to 12 weeks

descriptive

Primary/protocol endpoint

fasting glycemia

Time frame:up to 12 weeks

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Cardiometabolic biomarkers

2 endpoints
Primary/protocol endpoint

lipid status, change in Total cholesterol (TC), low-density lipoprotein(LDL), high-density lipoprotein (HDL) and triglicerides

Time frame:up to 12 weeks

change from baseline, improvement

componentsTotal cholesterol, change, LDL-C, change, HDL-C, change, Triglycerides, change

Primary/protocol endpoint

Change in inflammation marker level: CRP,

Time frame:up to 12 weeks

hs-CRP, change

change from baseline, improvement

LOINC 30522-7

Other clinical outcomes

1 endpoint
Primary/protocol endpoint/low confidence

clinical characteristics of patients with psoriasis

Time frame:up to 12 weeks

descriptive, improvement

Other (unclassified)

3 endpoints
Primary/protocol endpoint/low confidence

Serum values of TNFa, IL-1b, IL-6, IL-17 and IL-23

Time frame:up to12 weeks

concentration, descriptive

Primary/protocol endpoint/low confidence

Correlation between the course and prognosis of the disease after the treatment

Time frame:up to 12 weeks

descriptive

Primary/protocol endpoint/low confidence

urate

Time frame:up to 12 weeks

descriptive

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.